Innate Immunity Stimulation during the COVID-19 Pandemic: Challenge by Parvulan

This medical article is extremely interesting: "Innate Immunity Stimulation during the COVID-19 Pandemic: Challenge by Parvulan"

A killed strain of bacteria was administered to patients to increase their immunity:

"Corynebacterium parvum administration to 4000 fragile immune-depressed and multimorbid patients treated with a killed C. parvum strain to enhance innate immunity, integrating the adaptative immune response for long-standing antinfectious resistance."

It was 4,000 patients, and it was a retrospective survey, but some of the outcomes were very interesting.

The authors suggest that this treatment improved the physical and mental health of the patients, which in turn probably made them better off during the covid-19 pandemic.

"Our results confirm that C. parvum is quite safe and effective in supporting immune-compromised patients when epidemic or pandemic events increase ... risk...."

This was particularly surprising:

"A quick (48-72 hours) symptoms improvement and/or complete regression of the herpetic eruptions was observed in 1000 affected patients with disappearance or relieve of herpetic neuralgia (reduced in 80% of cases); also full recovery or frequency reduction (30%) of recurrent cystitis and prostatitis in 120 affected patients."

The authors are part of the Second Opinion Medical Consultation Network.

As noted in the article, Corynebacterium parvum has been  renamed Cutibacterium acnes.

The link to the full text article is here: 

Palmieri B, Manenti A, Galotti F, VadalĂ  M. Innate Immunity Stimulation during the COVID-19 Pandemic: Challenge by Parvulan. J Immunol Res. 2022 Apr 29;2022:4593598. doi: 10.1155/2022/4593598. PMID: 35528612; PMCID: PMC9076318.

No comments: